Previous close | 54.09 |
Open | 54.09 |
Bid | 54.15 |
Ask | 55.45 |
Strike | 95.00 |
Expiry date | 2024-06-21 |
Day's range | 54.09 - 54.09 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.